Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$4.67
+1.6%
$3.86
$3.21
$7.18
$1.12B0.64.86 million shs3.12 million shs
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
$5.59
$5.58
$2.50
$5.62
$577.05M0.563.34 million shs2.09 million shs
Morphic Holding, Inc. stock logo
MORF
Morphic
$56.99
$56.76
$19.34
$57.00
$2.85B1.491.27 million shs400 shs
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
$6.47
$6.47
$5.73
$8.75
$644.67M0.01N/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$31.29
+2.9%
$27.53
$18.92
$81.73
$3.51B0.624.06 million shs2.40 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ardelyx, Inc. stock logo
ARDX
Ardelyx
+2.68%+9.79%+22.34%+8.24%-17.27%
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
0.00%0.00%0.00%0.00%0.00%
Morphic Holding, Inc. stock logo
MORF
Morphic
0.00%0.00%0.00%0.00%+2.37%
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
0.00%0.00%0.00%0.00%0.00%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
+0.70%+9.67%+10.26%+41.26%-43.86%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ardelyx, Inc. stock logo
ARDX
Ardelyx
4.4398 of 5 stars
3.53.00.04.42.52.50.6
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
N/AN/AN/AN/AN/AN/AN/AN/A
Morphic Holding, Inc. stock logo
MORF
Morphic
1.0287 of 5 stars
1.00.00.04.80.03.30.0
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
N/AN/AN/AN/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
3.9856 of 5 stars
3.51.00.04.72.52.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ardelyx, Inc. stock logo
ARDX
Ardelyx
3.00
Buy$10.89132.97% Upside
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
0.00
N/AN/AN/A
Morphic Holding, Inc. stock logo
MORF
Morphic
2.00
Hold$57.000.02% Upside
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
0.00
N/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
3.00
Buy$87.15178.51% Upside

Current Analyst Ratings Breakdown

Latest ARDX, MORF, SVA, VKTX, and BDSI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00
6/18/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
5/2/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $10.00
5/2/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Outperform$11.00
4/29/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$104.00
4/28/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$95.00 ➝ $75.00
4/24/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$105.00 ➝ $102.00
4/24/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00 ➝ $102.00
4/17/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00 ➝ $102.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$333.61M3.35N/AN/A$0.73 per share6.40
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
$166.70M3.46$0.36 per share15.42$1.90 per share2.94
Morphic Holding, Inc. stock logo
MORF
Morphic
$520K5,490.11N/AN/A$12.31 per share4.63
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
$448.27M1.44$0.17 per share38.95$120.83 per share0.05
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$7.90 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$39.14M-$0.22N/A15.08N/A-14.86%-34.45%-13.81%7/30/2025 (Estimated)
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
$84.86M$0.836.748.47N/A50.90%21.25%10.56%N/A
Morphic Holding, Inc. stock logo
MORF
Morphic
-$152.10M-$3.50N/AN/AN/AN/A-26.62%-25.74%N/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
-$99.92MN/A0.00N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$109.96M-$1.15N/AN/AN/AN/A-14.41%-14.02%7/23/2025 (Estimated)

Latest ARDX, MORF, SVA, VKTX, and BDSI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$0.12N/AN/AN/AN/AN/A
7/23/2025Q2 2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.44N/AN/AN/AN/AN/A
5/1/2025Q1 2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 million
4/23/2025Q1 2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.31-$0.41-$0.10-$0.41N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ardelyx, Inc. stock logo
ARDX
Ardelyx
N/AN/AN/AN/AN/A
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
N/AN/AN/AN/AN/A
Morphic Holding, Inc. stock logo
MORF
Morphic
N/AN/AN/AN/AN/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Latest ARDX, MORF, SVA, VKTX, and BDSI Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
--$55.007/8/20255/23/20257/7/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ardelyx, Inc. stock logo
ARDX
Ardelyx
1.04
4.12
3.81
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
0.29
2.45
2.17
Morphic Holding, Inc. stock logo
MORF
Morphic
N/A
24.13
24.13
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
N/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
44.25
44.25

Institutional Ownership

CompanyInstitutional Ownership
Ardelyx, Inc. stock logo
ARDX
Ardelyx
58.92%
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
64.40%
Morphic Holding, Inc. stock logo
MORF
Morphic
94.25%
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%

Insider Ownership

CompanyInsider Ownership
Ardelyx, Inc. stock logo
ARDX
Ardelyx
4.80%
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
9.98%
Morphic Holding, Inc. stock logo
MORF
Morphic
25.60%
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
12.79%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ardelyx, Inc. stock logo
ARDX
Ardelyx
90239.26 million227.77 millionOptionable
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
200103.23 million92.93 millionOptionable
Morphic Holding, Inc. stock logo
MORF
Morphic
10050.09 million37.27 millionOptionable
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
3,26199.64 million86.89 millionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20112.31 million107.71 millionOptionable

Recent News About These Companies

Futuristic laboratory, doctor or scientist holding glass tube, molecular and DNA structure, genetic research human biology and pharmaceutical technology, medical,science,development biological system — Photo
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
...

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Ardelyx stock logo

Ardelyx NASDAQ:ARDX

$4.67 +0.07 (+1.61%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

BioDelivery Sciences International stock logo

BioDelivery Sciences International NASDAQ:BDSI

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.

Morphic stock logo

Morphic NASDAQ:MORF

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Sinovac Biotech stock logo

Sinovac Biotech NASDAQ:SVA

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$31.29 +0.89 (+2.94%)
As of 03:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.